5% Off
Eposis2000 IU
Beacon Pharmaceuticals PLC
৳976.68
Add to cart
Epoetin2000 IU
IV/SC Injection
By
Best PriceTk /
1
Medicine overview
Indications of Epoetin 2000 IU
Epoetin 2000 IU is indicated for the treatment of- Anemia associated with Chronic Renal Failurenoncardiac
Theropeutic Class
Drugs for Haemolytic Hypoplastic & Renal Anemia
Pharmacology
Epoetin 2000 IU regulates erythropoiesis by stimulating the differentiation and proliferation of erythroid precursors, stimulating the release of reticulocytes into the circulation, and synthesis of cellular haemoglobin.
Absorption
Recombinant human Epoetin 2000 IU is available as epoetin alfa and epoetin beta which are used in the management of anaemias associated with CRF, cancer chemotherapy and anti-AIDS drug zidovudine.
Dosage of Epoetin 2000 IU
Treatment of anemia in chronic renal failure
Dosage:Epoetin 2000 IU is administered to maintain hemoglobin concentration between 11 to 12 g/dl and hematocrit of 33-36 % in adults
Starting dose
Dosage:Adult: Usually 50 to 100 lU/kg three times in a week (TIW) by IV or Subcutaneous route
Pediatric
Dosage:50 lU/kg TIW by IV or Subcutaneous route
Dose adjustment
Dosage:Dose should be increased if hematocrit doses not increase by 5 to 6 points after 8 weeks therapy, and hematocrit is below suggested target range
Notes:Dose should be reduced when hematocrit approaches 36% or hematocrit increases >4 points in any 2-week period
Maintenance dose
Dosage:Maintenance dose must be individualized for each patient
Notes:In patients undergoing dialysis, the median maintenance dose is 75 lU/kg TIW, with a range from 12.5 to 525 lU/kg TIW as directed by the physician. In CRF patients not on dialysis, maintenance dose is 75 to 150 lU/kg/week
Treatment of Anemia in Cancer Patients on Chemotherapy
Dosage:Starting dose: Adult: 150 lU/kg TIW by Subcutaneous route or 40,000 IU Subcutaneous route weekly
Pediatric
Dosage:25 to 300 lU/kg 3 to 7 times per week by Subcutaneous or IV route
Dose adjustment
Dosage:If the response is not satisfactory, the dose should be increased to 300 lU/kg TIW
Notes:If the hematocrit exceeds 40%, the dose should be withheld until the hematocrit falls to 36%. The dose should be reduced to 25% when treatment is resumed and titrated to maintain the desired hematocrit
Surgery Patients
Dosage:The recommended dose is 300 lU/kg/day subcutaneously for 10 days before surgery, on the day of surgery, and for 4 days after surgery
Notes:An alternate dose schedule is 600 lU/kg subcutaneously in once weekly dose (21, 14, and 7 days before surgery) plus a fourth dose on the day of surgery
Zidovudine-treated HIV-infected Patients
Dosage:Starting dose Adult: 100 lU/kg as an IV or Subcutaneous injection TIW for 8 weeks
Pediatric
Dosage:50 to 400 lU/kg 2 to 3 times per week by Subcutaneous or IV route
Dose adjustment
Dosage:If the response is not satisfactory, the dose should be increased by 50-1001U/kg TIW
Notes:Response should be evaluated every 4 to 8 weeks thereafter and the dose adjusted accordingly by 50 to 100 lU/kg increments TIW
Maintenance dose
Dosage:The dose is titrated to maintain the hematocrit between 33-36%
| Condition | Dosage | Notes |
|---|---|---|
| Treatment of anemia in chronic renal failure | Epoetin 2000 IU is administered to maintain hemoglobin concentration between 11 to 12 g/dl and hematocrit of 33-36 % in adults | |
| Starting dose | Adult: Usually 50 to 100 lU/kg three times in a week (TIW) by IV or Subcutaneous route | |
| Pediatric | 50 lU/kg TIW by IV or Subcutaneous route | |
| Dose adjustment | Dose should be increased if hematocrit doses not increase by 5 to 6 points after 8 weeks therapy, and hematocrit is below suggested target range | Dose should be reduced when hematocrit approaches 36% or hematocrit increases >4 points in any 2-week period |
| Maintenance dose | Maintenance dose must be individualized for each patient | In patients undergoing dialysis, the median maintenance dose is 75 lU/kg TIW, with a range from 12.5 to 525 lU/kg TIW as directed by the physician. In CRF patients not on dialysis, maintenance dose is 75 to 150 lU/kg/week |
| Treatment of Anemia in Cancer Patients on Chemotherapy | Starting dose: Adult: 150 lU/kg TIW by Subcutaneous route or 40,000 IU Subcutaneous route weekly | |
| Pediatric | 25 to 300 lU/kg 3 to 7 times per week by Subcutaneous or IV route | |
| Dose adjustment | If the response is not satisfactory, the dose should be increased to 300 lU/kg TIW | If the hematocrit exceeds 40%, the dose should be withheld until the hematocrit falls to 36%. The dose should be reduced to 25% when treatment is resumed and titrated to maintain the desired hematocrit |
| Surgery Patients | The recommended dose is 300 lU/kg/day subcutaneously for 10 days before surgery, on the day of surgery, and for 4 days after surgery | An alternate dose schedule is 600 lU/kg subcutaneously in once weekly dose (21, 14, and 7 days before surgery) plus a fourth dose on the day of surgery |
| Zidovudine-treated HIV-infected Patients | Starting dose Adult: 100 lU/kg as an IV or Subcutaneous injection TIW for 8 weeks | |
| Pediatric | 50 to 400 lU/kg 2 to 3 times per week by Subcutaneous or IV route | |
| Dose adjustment | If the response is not satisfactory, the dose should be increased by 50-1001U/kg TIW | Response should be evaluated every 4 to 8 weeks thereafter and the dose adjusted accordingly by 50 to 100 lU/kg increments TIW |
| Maintenance dose | The dose is titrated to maintain the hematocrit between 33-36% |
Administration of Epoetin 2000 IU
Do not shake. It is not necessary to shake Epoetin 2000 IU. Prolonged vigorous shaking may denature any glycoprotein, rendering it biologically inactive.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.
Administer as an intravenous injection over 1-2 minutes. In patients on dialysis, the injection should follow the dialysis procedure. Slow injection over 5 minutes may be beneficial to those who experience flu-like symptoms.
Do not administer by intravenous infusion or in conjunction with other drug solutions.
For the subcutaneous route, a maximum of 1 ml_ at one injection site should generally not be exceeded. In the case of larger volumes, more than one site should be chosen for the injection.
Interaction of Epoetin 2000 IU
Haematinics enhance efficiency. Increased dose of heparin in patients undergoing dialysis.
Contraindications
Epoetin 2000 IU is contraindicated in patients with:
Uncontrolled hypertension
Known hypersensitivity to mammalian cell-derived products
A history of hypersensitivity to Epoetin 2000 IU or any component of the preparation.
Side Effects of Epoetin 2000 IU
General: Headache, dizziness, fever, malaise, arthralgia and occasionally hyperkalemia. Cardiovascular: Hypertension is the most common side effect, palpitations. Gastrointestinal: Nausea, vomiting, anorexia and diarrhea may occur occasionally. Allergic reactions.
Pregnancy & Lactation
Pregnant woman: There are no controlled studies of Epoetin 2000 IU in pregnant women. Therefore, Epoetin 2000 IU should be used during pregnancy only if Epoetin 2000 IU is clearly needed.Nursing mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Epoetin 2000 IU is administered to a nursing woman.
Precautions & Warnings
Epoetin 2000 IU should be used with caution in those patients with controlled hypertension, ischaemic vascular disease, history of seizures, or suspected allergy to the product.Iron evaluation: Prior to and during Epoetin 2000 IU therapy, the patient's iron stores, including transferrin saturation and serum ferritin, should be evaluated. Transferrin saturation should be at least 20%, and ferritin should be at least 100 ng/ml. Virtually all patients will require supplemental Iron to increase or maintain transferrin saturation to levels that will adequately support erythropoiesis.
Overdose Effects of Epoetin 2000 IU
Doses of up to 1500 lU/kg TIW for 3 to 4 weeks have been administered to adults without any direct toxic effects. If the suggested target range is exceeded, drug therapy may be temporarily withheld until the hemoglobin returns to the suggested target range. If polycythemia is of concern, phlebotomy may be indicated to decrease the hemoglobin.
Storage Conditions
Epoetin 2000 IU should be stored at 2°C to 8°C. Protect from light. Do not freeze & avoid shaking.
Drug Classes
Drugs for Haemolytic Hypoplastic & Renal Anemia
Pregnancy
Pregnancy Category C. Since there are no controlled studies of Epoetin 2000 IU in pregnant women, and because animal reproduction studies are not always predictive of human responses, Epoetin 2000 IU should be used during pregnancy only if clearly needed. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Epoetin 2000 IU is administered to a nursing woman.
Frequently Asked Questions
What is Epoetin 2000 IU used for?
Erythropoietin is indicated for the treatment of- Anemia associated with Chronic Renal Failure, including patients on dialysis and patients not on dialysis. Anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. ... Read moreErythropoietin is indicated for the treatment of- Anemia associated with Chronic Renal Failure, includi…
What is the dosage of Epoetin 2000 IU?
Treatment of anemia in chronic renal failure: Erythropoietin is administered to maintain hemoglobin concentration between 11 to 12 g/dl and hematocrit of 33-36 % in adults.Starting dose: Adult: Usually 50 to 100 lU/kg three times in a week (TIW) by IV or Subcutaneous route. Pediatric: 50 lU/kg TIW by IV or Subcutaneous route. Dose adjustment: Dose should be increased if hematocrit doses not increa…
What are the side effects of Epoetin 2000 IU?
General: Headache, dizziness, fever, malaise, arthralgia and occasionally hyperkalemia. Cardiovascular: Hypertension is the most common side effect, palpitations. Gastrointestinal: Nausea, vomiting, anorexia and diarrhea may occur occasionally. Allergic reactions.
Who should not take Epoetin 2000 IU?
Erythropoietin is contraindicated in patients with: Uncontrolled hypertension Known hypersensitivity to mammalian cell-derived products A history of hypersensitivity to Erythropoietin or any component of the preparation.
What precautions should be taken with Epoetin 2000 IU?
Erythropoietin should be used with caution in those patients with controlled hypertension, ischaemic vascular disease, history of seizures, or suspected allergy to the product.Iron evaluation: Prior to and during Erythropoietin therapy, the patient's iron stores, including transferrin saturation and serum ferritin, should be evaluated. Transferrin saturation should be at least 20%, and ferritin sh…
Is Epoetin 2000 IU safe during pregnancy and breastfeeding?
Pregnant woman: There are no controlled studies of erythropoietin in pregnant women. Therefore, erythropoietin should be used during pregnancy only if erythropoietin is clearly needed.Nursing mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when erythropoietin is administered to a nursing woman.
Disclaimer
The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.